Australia's most trusted
source of pharma news
Wednesday, 25 February 2026
Posted 24 February 2026 PM
Novo Nordisk's much hyped GLP-1/amylin combo CagriSema has been found to be less effective than Lilly's obesity shot Mounjaro, the blow sending the company's share price tumbling by more than 15 per cent.
Announcing the Phase 3 headline results from REDEFINE 4, a head-to-head trial comparing CagriSema and Mounjaro, Novo's hopeful demonstrated a 23 per cent weight loss after 84 weeks compared to 25.5 per cent for patients using Lilly's blockbuster.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.